Advertisement

Tailor the management of H. pylori infection in paediatric patients to antimicrobial susceptibility profiles

  • Adis Medical WritersEmail author
Disease Management
  • 9 Downloads

Abstract

Infection with Helicobacter pylori (H. pylori) is highly prevalent worldwide, is typically acquired during childhood and, if left untreated, is the major cause of numerous complications, such as chronic gastritis and peptic ulcer disease. Management of H. pylori infection in paediatric patients differs to that of adults, and should be tailored to the antimicrobial susceptibility profile of the patient in order to achieve optimal efficacy.

Notes

Compliance with ethical standards

Conflict of interest

The article was adapted from Pediatric Drugs 2018;20(4):337–51 by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

References

  1. 1.
    Kotilea K, Kalach N, Homan M, et al. Helicobacter pylori infection in pediatric patients: update on diagnosis and eradication strategies. Pediatr Drugs. 2018;20(4):337–51.CrossRefGoogle Scholar
  2. 2.
    Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9.CrossRefGoogle Scholar
  3. 3.
    Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868–76.CrossRefGoogle Scholar
  4. 4.
    Yang HR. Updates on the diagnosis of Helicobacter pylori infection in children: what are the differences between adults and children? Pediatr Gastroenterol Hepatol Nutr. 2016;19(2):96–103.CrossRefGoogle Scholar
  5. 5.
    Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;64(6):991–1003.CrossRefGoogle Scholar
  6. 6.
    Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53(2):230–43.Google Scholar
  7. 7.
    Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12(2):177–186.e3.CrossRefGoogle Scholar
  8. 8.
    Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.CrossRefGoogle Scholar
  9. 9.
    Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;(12):CD008337.Google Scholar
  10. 10.
    Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.CrossRefGoogle Scholar
  11. 11.
    Hurduc V, Plesca D, Dragomir D, et al. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr. 2008;98(1):127–31.CrossRefGoogle Scholar
  12. 12.
    Lionetti E, Miniello VL, Castellaneta SP, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther. 2006;24(10):1461–8.CrossRefGoogle Scholar
  13. 13.
    Sykora J, Valeckova K, Amlerova J, et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J Clin Gastroenterol. 2005;39(8):692–8.CrossRefGoogle Scholar
  14. 14.
    Wang YH, Huang Y. Effect of Lactobacillus acidophilus and Bifidobacterium bifidum supplementation to standard triple therapy on Helicobacter pylori eradication and dynamic changes in intestinal flora. World J Microbiol Biotechnol. 2014;30(3):847–53.CrossRefGoogle Scholar
  15. 15.
    Li B-Z, Threapleton DE, Wang J-Y, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations